Three young scientists from Aragon: "It's a blessing to dedicate yourself to research with a contract"
23 April 2026
The third edition of "Conquering the territory of autoimmunity" continues at the Lozano Blesa University Clinical Hospital
27 April 2026
The panels in May will address the use of Paxlovid in COVID-19 and the treatment of hyponatremia with urea in clinical practice
The Internal Medicine Service of the Lozano Blesa University Clinical Hospital continues with its training program “Thursday Sessions“,” an initiative that brings together healthcare professionals for clinical discussion panels on current topics. These sessions, held in the classroom on the 12th floor of the hospital, are led by Dr. Adela Marín and are part of the 2026 annual program.
Following the sessions already held on January 22, On the FSL Program; the February 5, about the New frontiers in the treatment of Progressive Pulmonary Fibrosis in EAS; the February 26On dapagliflozin and the combinations that follow; the March 12., On the phenotype of a PE patient prone to developing chronic thromboembolic disease and pulmonary hypertension; and the March 26., On the Diagnosis and treatment of pulmonary arterial hypertension from emergency admissionThe cycle now reaches its May meetings with two new panels focused on issues of special interest to clinical practice.
During the month of May, the program includes two meetings focused on key issues for clinical practice. The first session, which will take place on May 7th, will focus on “When, to whom and where to prescribe Nirmatrelvir-ritonavir (Paxlovid)"and will feature Dr. Gloria SamperizThe debate will focus on the role of this treatment in the management of COVID-19, the optimal time to start, the patient profiles that benefit the most —especially those at high risk of progression to severe disease— and the different care settings in which it can be indicated, such as primary care, emergency, hospitalization or outpatient settings.
In addition, fundamental aspects such as eligibility criteria, contraindications, possible drug interactions and their integration into routine clinical circuits will be addressed, with the aim of optimizing their use in real practice.
The second session, scheduled for the May 14th, will be dedicated to “Rivaroxaban in deep vein thrombosis and pulmonary embolism. 2026 Update”The session will feature the following speaker: Juan Diego, MSL of Servier, and will allow a review of the latest developments and key aspects in the use of rivaroxaban in the treatment of deep vein thrombosis and pulmonary embolism.
Finally, the third table, scheduled for the May 28th, it will be a “Clinical Session on Hyponatremia, when the treatment is with UreaIt will be taught by Dr. Vanesa Garcés and will delve into the indications, mechanisms of action, clinical results and safety profile of urea treatment, as well as its application in different healthcare contexts.
